Browse
Submit Data
Databases
API
Help

Dataset Information

23 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Efficacy of Oxycodone/Naloxone(OXN), Versus Oxycodone (OXY), for the Reduction of Intensity of Opioid-induced Constipation in Pain Patients

ABSTRACT: The primary objective of this trial is to study the efficacy of oxycodone/naloxone prolonged release tablets (OXN PR), compared to oxycodone prolonged release tablets (Oxy PR), for the reduction of the intensity of opioid-induced constipation symptoms in patients treated for cancer or non-cancer pain.

DISEASE(S): Pain,For Both Compounds, Treatment For Cancer Or Non-cancer Pain, Adult Subjects With A Diagnosis Of Cancer Pain Or Non-cancer Pain Such As Chronic Low Back Pain, Osteoarthritis Or Other.only For Targinact, The Intention Of Naloxone Is To Reduce The Intensity Of Opioid-induced Constipation Symptoms.,Opioid-induced Constipation,Constipation,For Both Compounds, Treatment For Cancer Or Non-cancer Pain, Adult Subjects With A Diagnosis Of Cancer Pain Or Non-cancer Pain Such As Chronic Low Back Pain, Osteoarthritis Or Other.only For Targi...

PROVIDER: 2080860 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Oxycodone-naloxone Prolonged Release Tablets in Relieving Opioid-related Constipation

Project description:The primary objective is to demonstrate that patients taking oxycodone/naloxone prolonged release tablets have improvement in symptoms of constipation compared to subjects taking oxycodone prolonged release tablets alone.

| 2035373 | ecrin-mdr-crc

Oxycodone-naloxone in Relieving Opioid-related Constipation

Project description:The primary objective of this study is to demonstrate that subjects with moderate to severe non-malignant pain taking oxycodone/naloxone prolonged release tablets have improvement in symptoms of constipation compared to subjects taking oxycodone prolonged release tablets alone.

| 2035377 | ecrin-mdr-crc

Clinical study to investigate the efficacy, safety and tolerability of Naloxone in patients with opioid induced constipation.

Project description:Primary objectives: The primary objective of the trial is to demonstrate that administration of Naloxone HCl PR (prolonged-release) tablets twice daily is superior to Naloxone HCl PR Placebo in the improvement / reversal of opioid-induced constipation as determined by the bowel function index (BFI). Primary end point is defined as the absolute change in BFI score at the end of Week 12 (Visit 11) compared to baseline (Visit 4)

| 2531166 | ecrin-mdr-crc

Clinical study to investigate the efficacy, safety and tolerability of Naloxone in patients with opioid induced constipation.

Project description:Primary objectives: The primary objective of the trial is to demonstrate that administration of Naloxone HCl PR (prolonged-release) tablets once daily is superior to Naloxone HCl PR Placebo in the improvement / reversal of opioid-induced constipation (OIC) as determined by the Bowel Function Index (BFI). Primary end point is defined as the absolute change in BFI score at the end of Week 12 (Visit 11) compared to baseline (Visit 4).

| 2531364 | ecrin-mdr-crc

A Study Comparing Oxycodone to Oxycodone/Naloxone in Moderate to Severe, Chronic Cancer Pain

Project description:The purpose of this study is to test the oxycodone/naloxone combination compared to oxycodone alone in patient’s specific type of "chronic cancer pain".

| 2043021 | ecrin-mdr-crc

To Demonstrate Equivalence in Analgesic Efficacy & Bowel Function Between OXN PR Higher Dose & Lower Dose Tablet Strengths in Subjects With Non-cancer or Cancer Pain

Project description:This study is aimed to demonstrate equivalence between combinations of lower strength OXN PR tablets (OXN PR LST) and single higher strength OXN PR tablets (OXN PR HST) taken at the same overall daily dose.

| 2180617 | ecrin-mdr-crc

Naloxone influences NSCs proliferation and differentiation

Project description:Naloxone is an opioid-receptor antagonist used to reverse the effects of opioid.In our study, we treated NSCs (neural stem cells) with naloxone and damgo (a selective μopioid receptor agonist), and examined their effects on NSCs proliferation and differentiation.Naloxone was found to promote NSCs proliferation and neural differentiation, while the effects of damgo was very week. The results suggested that naloxone may work indepedent of opioid receptors. To investigate the underlying mechanisms, RNA-seq was conducted. For proliferation analysis,p8 NSCs were cultured with or without naloxone or damgo for 3 days. For differentiation analysis,p8 NSCs was induced to differentiate with or without naloxone or damgo, samples on D2,4,8 were collected and analyzed.

2020-03-04 | GSE106376 | GEO

DNA methylation maps of mouse NSCs treated with naloxone

Project description:In our study,we examined the effects of naloxone (an opioid receptor antagonist) on NSCs (neural stem cells) proliferation and differenntiation. Briefly, we treated NSCs with naloxone in the proliferation and differentiation system. Naloxone was shown to acclerate NSCs proliferation and increase neural differentiation.To investigate how DNA methylation is affected upon naloxone treatment, cells cultured 3 days with naloxone and cells differentiated with naloxone at D2 were collected, genomic DNA was extracted and subjected to RRBS analysis.

2020-03-04 | GSE107525 | GEO

Effects of naloxone on NSC proliferation and differentiation

2020-10-27 | GSE106263 | GEO

Genome-wide analysis of dorsal root ganglion (DRG) gene expression after morphine or oxycodone treatment

Project description:Analyse of gene expression modification after chronic analgesic treatment. The hypothesis tested in the present study was that oxycodone and morphine induced gene expression modification. Results provide important information to understand the analgesic effects of oxycodone as compared to morphine in a neuropathic pain model Total RNA obtained from DRG of neuropathic or control animals after oxycodone or morphine treatment

2014-01-09 | E-GEOD-53897 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data